title: FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors.
abstract: OBJECTIVE
  To evaluate the role of positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose (FDG-PET) in 31 patients with evidence of intracranial metastatic disease.
  
  
  METHODS
  PET was used to evaluate the intracranial lesions for glucose hypermetabolism to suggest malignancy, mutiplicity of intracranial lesions, and extracranial foci or sources of disease. Patients with proven malignant intracranial lesions subsequently underwent further corroborative radiologic tests and histologic examination to confirm staging and primary location.
  
  
  RESULTS
  PET identified focal hypermetabolic abnormalities in 19 of 22 intracranial metastases, 2 hypometabolic lesions, and 1 renal cell tumor embolism that hemorrhaged (hypometabolic lesion). It also identified 82% of extracranial primary tumor sites, of which 55% were found only on PET and not on conventional diagnostic tests.
  
  
  CONCLUSIONS
  FDG-PET may prove valuable in the initial work-up of patients with suspected intracranial metastases.
authors.affiliation: WVU PET Center and Department of Neurosurgery, School of Medicine, West Virginia University, Morgantown 26506-9236, USA.
authors.forename: N C
authors.initials: NC
authors.lastname: Gupta
authors.forename: P
authors.initials: P
authors.lastname: Nicholson
authors.forename: S M
authors.initials: SM
authors.lastname: Bloomfield
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000556:secondary*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009367:Neoplasm Staging; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18